Transaction DateRecipientSharesTypePriceValue
12th February 2021Advisors Llc Orbimed104,050Grant/award etc.$13.00$1,352,650.00
12th February 2021Advisors Llc Orbimed420,299Grant/award etc.$13.00$5,463,887.00
9th February 2021Advisors Llc Orbimed1,989,723Conversion of derivative$0.00
9th February 2021Advisors Llc Orbimed1,326,481Conversion of derivative$0.00
9th February 2021Advisors Llc Orbimed190,000Open or private purchase$17.00$3,230,000.00
9th February 2021Advisors Llc Orbimed285,000Open or private purchase$17.00$4,845,000.00
22nd January 2021Advisors Llc Orbimed13,822,463Disposition due to a tender of shares in a change of control transaction$0.00
7th January 2021Advisors Llc Orbimed2,000,000Open or private sale$3.50$7,000,000.00
28th December 2020Advisors Llc Orbimed600,000Open or private sale$14.25$8,550,000.00
8th December 2020Venture Investments, Llc Alexandria699,412Conversion of derivative$0.00
Next Cure
Next Cure logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

NextCure, Inc. is a clinical-stage biopharmaceutical company. It is developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function.

Ticker: NXTC
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1661059
Employees: 44
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags